Diuretic Agents – Comprehensive Study Notes

Case Study Summary

  • 65-year-old man with diabetes and chronic kidney disease (baseline creatinine 2.2 mg/dL) on furosemide 80 mg PO twice daily for edema and hypertension.
  • Hydrochlorothiazide (HCTZ) 25 mg daily added for better BP control and fluid overload symptoms.
  • Two weeks later: weakness, anorexia, malaise; BP 91/58 mm Hg; weight loss ~15 kg in 2 weeks; serum creatinine 10.8 mg/dL.
  • Question: What caused AKI? Why weight loss? What precautions could have avoided hospitalization?
  • Answer (from text): Addition of a thiazide to chronic loop diuretic therapy produced dramatic diuresis, leading to hypovolemia and AKI in a patient with preexisting CKD. This case highlights the need for very close monitoring when adding a thiazide to loop diuretics, especially in CKD; inpatient monitoring is often advisable.

Key Concepts and Definitions

  • Diuretic terminology
    • Diuretic: agent that increases urine volume.
    • Natriuretic: increases renal Na+ excretion.
    • Aquaretic: increases excretion of solute-free water.
    • Natriuretic diuretics: typically cause some water loss as well; often just called diuretics.
    • Urearetics: urease transport blockers; increase urine output and urea excretion without increasing electrolyte excretion; aquaretics in early investigational stages.
  • Historical timeline (renal diuresis foundations)
    • Carbonic anhydrase inhibitors first described in 1937.
    • Chlorothiazide (a thiazide) became available in 1957 and was a major advance in diuretic therapy.
  • Nephron transport overview
    • Nephron segments arranged from proximal to collecting duct: PCT → Loop (Henle) → DCT → Collecting system.
    • Transporters and targets in apical membranes include NHE3, CA, SGLT2 in PCT; NKCC2 in TAL; NCC in DCT; ENaC/K+ channels in collecting duct; aquaporins (AQP1 in PCT-descending limb; AQP2 regulated by ADH in collecting duct).
    • Water reabsorption is tightly linked to solute reabsorption; many diuretics act by inhibiting specific transporters to disrupt Na+ (and water) reabsorption.
  • Autacoids in renal physiology
    • Adenosine, prostaglandins (notably PGE2), and urodilatin influence renal function and diuretic responses.
    • NSAIDs can blunt prostaglandin synthesis and thereby interfere with diuretic action (notably loop diuretics).
  • SGLT2 inhibitors: glucose reabsorption and diuresis
    • Inhibit Na+/glucose cotransporter 2 in PCT; cause osmotic diuresis and mild natriuresis; have pronounced cardioprotective and renoprotective effects beyond glucose lowering.

Nephron Segments and Major Transporters (Functional Map)

  • Glomerulus
    • Filtration: formation of glomerular filtrate; no direct transporters for diuretic targets.
  • Proximal convoluted tubule (PCT)
    • Reabsorption: ~65% Na+/K+/Ca2+/Mg2+; ~85% NaHCO3; ~100% glucose and amino acids.
    • Water reabsorption: isosmotic, via transcellular (AQP1) and paracellular pathways.
    • Apical transporters/targets: Na+/H+ exchanger 3 (NHE3); carbonic anhydrase (CA); Na/glucose cotransporter 2 (SGLT2).
    • Diuretic actions: Carbonic anhydrase inhibitors block NaHCO3 reabsorption; SGLT2 inhibitors affect glucose and Na+ reabsorption (diuretic effect mainly osmotic, with natriuretic component).
  • Proximal tubule straight segment (S2)
    • Secretory systems for organic acids (e.g., uric acid, diuretics) and organic bases (creatinine, choline).
  • Descending thin limb of Henle
    • Water reabsorption via aquaporins; high water permeability.
  • Thick ascending limb (TAL)
    • Active Na+/K+/2Cl− cotransport (NKCC2) reabsorption (~15–25% of filtered Na+).
    • Water impermeable; diluting segment.
    • Divalent cation reabsorption (Mg2+/Ca2+) via lumen-positive potential from K+ recycling (ROMK-mediated back-diffusion).
    • Major diuretic target: loop diuretics block NKCC2.
  • Distal convoluted tubule (DCT)
    • NaCl reabsorption via Na+/Cl− cotransporter (NCC).
    • Calcium reabsorption regulated by PTH via basolateral Na+/Ca2+ exchanger.
  • Cortical collecting tubule (CCT) and collecting duct
    • Na+ reabsorption via ENaC; K+ secretion via K+ channels; water reabsorption regulated by ADH via AQP2 trafficking.
    • Aldosterone enhances expression and activity of ENaC and Na+/K+ ATPase, increasing Na+ reabsorption and K+ secretion.
    • Intercalated cells secrete H+ (α) or HCO3− (β).
  • Medullary collecting duct
    • Final site for urine concentration; ADH controls water permeability via AQP2; UT-A1 (urea transporter) involvement in medullary concentrating mechanism.

Major Diuretic Drug Classes: Mechanisms, Targets, and Effects

  • Carbonic anhydrase inhibitors (e.g., acetazolamide)
    • Mechanism: Inhibit CA in PCT; disrupt HCO3− reabsorption and Na+ reabsorption; cause bicarbonaturia and metabolic acidosis.
    • Pharmacokinetics: Rapid oral absorption; urine pH increases within ~30 minutes; excretion via S2 segment; dose reduction needed in renal impairment.
    • Major actions: Diuresis is self-limiting (about 2–3 days) due to downstream compensation; inhibits ~85% of superficial PCT HCO3− reabsorption at max dose; overall inhibition ~45% of whole-kidney HCO3− reabsorption.
    • Clinical uses: Glaucoma (reduction of aqueous humor formation); mountain sickness; certain cases of metabolic alkalosis; CSF leakage reduction; adjunct in epilepsy and other conditions. Notable adverse effects: hyperchloremic metabolic acidosis, renal stones, possible hypophosphatemia; hyperammonemia risk in cirrhotics; potential for AKI with crystal precipitation and intratubular obstruction.
    • Interactions/limits: NSAIDs can reduce efficacy; overall limited diuretic use due to acidosis and electrolyte disturbances.
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin)
    • Mechanism: Inhibit SGLT2 in PCT; reduce Na+ and glucose reabsorption; osmotic diuresis contributes to diuretic effect; also natriuretic effect.
    • Pharmacokinetics: Rapid GI absorption; half-lives ~10–12 h (dapagliflozin); up to ~70% excreted as glucuronide; some activity in CKD patients albeit reduced efficacy with lower eGFR.
    • Clinical indications: Diabetes mellitus (primary); cardioprotective and renoprotective benefits; approved for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status; potential AKI risk in some contexts; generally minimal electrolyte disturbance.
    • Adverse effects: Rare hypoglycemia; genital fungal infections; modestly increased UTI risk; no major electrolyte shifts; potential AKI signals with some regimens; initial GFR drop may occur (class effect).
  • Loop diuretics (e.g., furosemide, bumetanide, torsemide, ethacrynic acid)
    • Mechanism: Inhibit NKCC2 in TAL; block NaCl reabsorption; reduce lumen-positive potential, increasing Mg2+ and Ca2+ excretion; diuresis often profound.
    • Pharmacokinetics: Rapid absorption; furosemide renal and secretory handling; torsemide and bumetanide more consistent bioavailability; duration 2–6 h depending on agent; NSAIDs or probenecid can reduce secretion and diuretic effect.
    • Potency/relative dosing: Relative potency (approximate) — Furosemide 20 mg ≈ Torsemide 10 mg ≈ Bumetanide 0.5 mg ≈ Ethacrynic acid ~50 mg.
    • Clinical uses: Acute pulmonary edema, edema, hypertension, hypercalcemia, hyperkalemia, acute renal failure, and certain overdoses.
    • Pharmacodynamics: Can cause significant K+ wasting and hypomagnesemia; calcium excretion increases (risk of hypocalcemia is low if volume depletion is managed); PGE2 induction by loop diuretics contributes to diuretic effect; NSAIDs can blunt loop effect by reducing renal prostaglandins.
    • Adverse effects: Hypokalemic metabolic alkalosis; ototoxicity (especially with high doses or concomitant ototoxic drugs); hyperuricemia and gout; hypomagnesemia; potential hypersensitivity (sulfonamide allergy for most loops except ethacrynic acid).
  • Thiazide and thiazide-like diuretics
    • Mechanism: Inhibit Na+/Cl− cotransport (NCC) in the DCT; reduce NaCl reabsorption; mild diuresis.
    • Calcium effects: Increase Ca2+ reabsorption in DCT; may prevent calcium-containing stones; may reduce fracture risk; NSAIDs can blunt their effects.
    • Pharmacokinetics: All thiazides secreted by the organic acid secretory system; variations in bioavailability (e.g., chlorothiazide IV form available); metolazone useful in loop-resistant cases; chlorthalidone has long half-life and potent BP effects.
    • Clinically: Hypertension, heart failure, nephrolithiasis due to idiopathic hypercalciuria, nephrogenic diabetes insipidus.
    • Adverse effects: Hypokalemic metabolic alkalosis; hyponatremia (elderly women especially at risk); hyperuricemia and gout risk; impaired carbohydrate tolerance (hyperglycemia) in higher doses; increased cholesterol; photosensitivity; possible skin cancers risk with long-term use; rare lupus-like syndrome; hypomagnesemia.
    • Interactions: NSAIDs may reduce effect; cross-sensitivity in those with sulfa allergy; uric acid competition for organic acid secretory pathways can raise uric acid.
  • Potassium-sparing diuretics
    • Mechanisms and subclasses:
    • Aldosterone antagonists (spironolactone, eplerenone, newer nonsteroidal agents like finerenone, esaxerenone, apararenone): block action of aldosterone at the collecting duct to reduce Na+ reabsorption and K+ secretion.
    • Direct ENaC inhibitors (amiloride, triamterene): block Na+ entry at the luminal membrane of principal cells, reducing Na+ reabsorption and K+ secretion.
    • Other emerging agents (DSR-71167, baxdrostat) target mineralocorticoid pathways or aldosterone synthesis with less hyperkalemia risk.
    • Pharmacodynamics: Lower K+ loss downstream; aldosterone antagonists reduce Na+ reabsorption and K+ secretion; ENaC blockers have direct action on Na+ channels.
    • Clinical uses: Mineralocorticoid excess states, resistant hypertension, edema with aldosteronism; heart failure; nephrotic syndrome; some role in delaying CKD progression (finerenone).
    • Adverse effects: Hyperkalemia risk (especially with CKD, RAAS inhibitors, or other K+-sparing agents); gynecomastia with spironolactone (less with eplerenone and newer agents); metabolic acidosis (type IV RTA features) due to reduced H+ secretion; rare nephrotoxicity and drug interactions (CYP3A4 inhibitors can raise levels of certain nonsteroidal MR antagonists).
  • Osmotic diuretics
    • Agent: Mannitol (protptype).
    • Mechanism: Nonreabsorbed solute in glomerular filtrate retains water in proximal tubule and descending limb; decreases water reabsorption and increases urine flow; can cause hyponatremia initially followed by hypernatremia if overdiuresis occurs.
    • Indications: Reduce intracranial pressure and intraocular pressure; promote toxin elimination; avoid in patients with significant dehydration risk.
    • Pharmacokinetics: Not absorbed well orally; must be IV; not metabolized; rapidly filtered.
    • Adverse effects: Extracellular volume expansion; hyponatremia initially, then dehydration/hypernatremia; headaches, nausea; possible renal failure with overuse.
  • Antidiuretic hormone (ADH) antagonists (Vaptans)
    • Mechanism: Antagonize V1a/V2 receptors (conivaptan is V1a/V2; tolvaptan, lixivaptan, mozavaptan, satavaptan are V2-selective).
    • Clinical uses: SIADH; hyponatremia associated with heart failure; autosomal dominant polycystic kidney disease (tolvaptan slows cyst growth in PKD at higher doses but with potential liver toxicity).
    • Pharmacokinetics: Conivaptan and demeclocycline have 5–10 h half-life; tolvaptan ~12–24 h.
    • Adverse effects: Hypernatremia, hypotension; hepatic safety concerns with tolvaptan in chronic use; electrolyte disturbances generally limited; monitor liver function with PKD trials.
  • Urea transport inhibitors (urearetics)
    • Concept: Inhibit UT-A and UT-B uro-transporters to reduce medullary concentrating ability; increase urinary water excretion without major electrolyte loss.
    • Current status: Preclinical; potential utility in edema and SIADH; role relative to vaptans yet to be established.

Pharmacology: Detailed Drug-by-Drug Notes (Key Points)

  • Carbonic anhydrase inhibitors (acetazolamide, other related agents)
    • Sites of action: PCT and other CA-rich locations.
    • Effects: Alkalinization of urine; bicarbonaturia; metabolic acidosis; modest diuresis that wanes as downstream mechanisms compensate.
    • Clinical uses beyond diuresis: Glaucoma (reduce aqueous humor formation); mountain sickness prevention; CSF-related hormonal and metabolic processes; epilepsy adjuncts; nephrolithiasis with urinary alkalinization.
    • Toxicities: Hyperchloremic metabolic acidosis; renal stones; hypophosphatemia; hypokalemia possible; CNS effects with high dose; potential for AKI due to crystal precipitation.
  • SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin, ipragliflozin)
    • Benefits: Cardioprotective and renoprotective effects; reduction in heart failure hospitalization; slow CKD progression; modest weight loss; BP reduction; low hypoglycemia risk.
    • Limitations: Decreased efficacy with advanced CKD (reduced filtered load and glucose excretion); interactions with rifampin lowering exposure; variable diuretic effect in different patients.
  • Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid)
    • Major actions: Inhibit NKCC2 in TAL; strong diuretic effect; rapid onset.
    • Dosing considerations: Potency varies; timing and route (IV vs oral) matter; NSAIDs and probenecid can reduce secretion and effect.
    • Key toxicities: Hypokalemia and metabolic alkalosis; ototoxicity (especially with high dose or concurrent ototoxic drugs); hyperuricemia and gout; hypomagnesemia; allergic reactions (sulfonamide allergy except ethacrynic acid).
  • Thiazides and thiazide-like diuretics
    • Major actions: Inhibit NCC in DCT; milder diuresis than loops; increase Ca2+ reabsorption.
    • Notable agents and dosing diversity: HCTZ, chlorthalidone (long half-life), indapamide, metolazone (often used with loop diuretics for synergy), chlorothiazide (IV form).
    • Adverse effects: Hyponatremia, hypokalemia, hyperuricemia, hyperglycemia at higher doses; photosensitivity; potential skin cancer risk (varies by agent and exposure); rare lupus-like reactions.
  • Potassium-sparing diuretics
    • Aldosterone antagonists: spironolactone (also antiandrogen effects causing gynecomastia), eplerenone (more selective for MR receptor, fewer antiandrogenic effects), finerenone (nonsteroidal MR antagonist with kidney-selective effects), esaxerenone, apararenone (newer agents).
    • ENaC inhibitors: amiloride, triamterene (often used with thiazides or loops to prevent K+ loss or Li+ induced nephrogenic DI).
    • Clinical uses: Hyperaldosteronism, resistant hypertension, edema with CKD; treatment of nephrogenic DI (especially Li+-induced).
    • Adverse effects: Hyperkalemia risk (especially with CKD and RAAS inhibitors); gynecomastia mainly with spironolactone; metabolic acidosis; interactions with NSAIDs and ACE inhibitors/ARBs.
  • Osmotic diuretics (mannitol)
    • Mechanism: Osmotic effect in proximal nephron and descending limb; increases free water excretion; can worsen extracellular volume in susceptible patients.
    • Use cautions: Avoid in overt heart failure; monitor for hyponatremia/hypernatremia.
  • ADH antagonists (conivaptan, tolvaptan, lixivaptan, mozavaptan, satavaptan)
    • Indications: SIADH; hyponatremia with HF; PKD (tolvaptan).
    • Safety: Hepatotoxicity concerns (tolvaptan at high doses); hyponatremia correction needs monitoring; conivaptan IV only; monitoring for hypotension.
  • Urearetics (urea transport inhibitors)
    • Preclinical; potential renal and fluid management roles; not yet standard therapy.

Clinical Applications and Practical Considerations

  • Edema management and fluid overload
    • Loop diuretics are first-line for acute pulmonary edema and edema associated with heart failure, nephrotic syndrome, liver disease, and other edematous states.
    • When diuretic resistance occurs, combining loop with thiazide (e.g., metolazone) can produce a synergistic effect by blocking Na+ reabsorption at multiple nephron sites (TAL and DCT).
    • In CKD or dialysis candidates, high-dose loop diuretics or loop plus metolazone can be used to manage volume overload, with careful monitoring for electrolyte disturbances and renal function.
  • Hypertension
    • Thiazides (particularly chlorthalidone) are effective for essential hypertension and may outperform some alternatives in certain populations; however, risk of hyponatremia, hyperglycemia, and lipid changes requires monitoring.
    • Combination therapy with ACE inhibitors or ARBs is common and can enhance antihypertensive efficacy; spironolactone has shown benefits in resistant hypertension.
  • Nephrolithiasis and hypercalciuria
    • Thiazides reduce urinary calcium excretion and can prevent calcium-containing stones; adequate dietary calcium should be maintained; salt restriction assists.
  • CKD and kidney disease considerations
    • Loop diuretics are often needed in CKD with edema; thiazides may still be useful in CKD patients with eGFR down to ~30 mL/min and sometimes with metolazone in combination.
    • Acetazolamide generally avoided in significant CKD due to acidosis risk; K+-sparing diuretics require cautious use due to hyperkalemia risk in CKD.
  • Liver disease and ascites (cirrhosis)
    • Spironolactone (MR antagonism) is particularly effective for cirrhotic edema/ascites; combination with loop diuretics may be necessary in refractory cases but requires careful monitoring for hyperkalemia and renal function.
  • Hyponatremia risk and safety monitoring
    • Loop diuretics have relatively lower hyponatremia risk compared with thiazides; thiazides increase hyponatremia risk substantially, particularly in elderly women.
  • SGLT2 inhibitors in cardiovascular and renal protection
    • Beyond glucose lowering, SGLT2 inhibitors reduce hospitalization for heart failure and slow CKD progression; potential AKI signals exist; monitor renal function and electrolytes as per guidelines.

Special Concepts and Mechanisms (Key Takeaways)

  • Calcium and magnesium handling in TAL and DCT
    • NKCC2 inhibition by loop diuretics reduces lumen-positive potential, reducing Mg2+ and Ca2+ reabsorption; loops cause calciuria and hypomagnesemia; thiazides increase Ca2+ reabsorption and can cause hypocalcemia less often.
  • Urea handling and medullary concentration
    • Urea flux and UT transporters contribute to medullary hypertonicity; urearetics and ADH-modulating therapies influence urine concentration and osmolality.
  • Prostaglandin interactions
    • PGE2 blunts Na+ reabsorption in TAL and modulates ADH-dependent water transport; NSAIDs can blunt loop and thiazide effects by inhibiting COX and prostaglandin synthesis.
  • Autacoids and diuretic pharmacology
    • Adenosine receptor modulation (A1) affects NHE3 activity and GFR; A1 antagonists increase diuresis without causing potassium wasting in some contexts.
  • RAAS interactions and potassium balance
    • Aldosterone antagonists reduce K+ loss; combining loop or thiazide diuretics with MR antagonists increases risk of hyperkalemia, especially in CKD or when RAAS is inhibited.

Important Formulas and Numerical References (LaTeX format)

  • Nephron segment transporters (conceptual equations)
    • TAL Na+/K+/2Cl− cotransport (NKCC2):
      ext{Na}^+ + ext{K}^+ + 2 ext{Cl}^-
      ightarrow ext{transport into TAL cell}
    • Distal convoluted tubule NCC transporter:
      ext{Na}^+ + ext{Cl}^-
      ightarrow ext{NaCl reabsorption via NCC}
    • Collecting duct ENaC and aldosterone effect:
      ext{Na}^+ ext{ entry through ENaC}
      ightarrow ext{Na}^+ ext{ reabsorption; K}^+ ext{ secretion}
  • Proportions of reabsorption in PCT (normal human physiology)
    • Proximal tubule reabsorbs approximately 66extextpercent66 ext{ extpercent} of filtered Na+ and 85extextpercent85 ext{ extpercent} of NaHCO3; 60extextpercent60 ext{ extpercent} of water; nearly all glucose and amino acids.
  • Water permeability in PCT
    • PCT water permeability extremely high; osmolality of tubular fluid remains nearly constant due to rapid water movement through aquaporin-1 (AQP1).
  • Quick reference dosing (typical values; in practice choose agent-specific dosing)
    • Loop diuretics: Furosemide 20–80 mg/day (oral); torsemide 5–20 mg; bumetanide 0.5–2 mg; Ethacrynic acid 50–200 mg.
    • Thiazides: Hydrochlorothiazide 25–100 mg/day; chlorthalidone 25–50 mg/day; indapamide 2.5–10 mg/day; metolazone 2.5–10 mg/day.
    • MR antagonists: Spironolactone 25–100 mg/day; Eplerenone 25–100 mg/day; Finerenone dosing varies by condition.
  • Glucose reabsorption and SGLT2 inhibitors (conceptual)
    • Inhibiting SGLT2 reduces glucose reabsorption and also reduces Na+ reabsorption in the proximal tubule, contributing to diuresis: see canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin.

Practical Precautions and Take-Home Messages

  • In patients with CKD or reduced renal function, adding a thiazide to a loop diuretic can cause excessive diuresis and AKI due to abrupt volume depletion. Close monitoring of weight, BP, serum creatinine, and electrolytes is essential; consider inpatient initiation or gradual dose titration.
  • Always assess volume status, electrolyte balance, and kidney function before escalating diuretic therapy, especially in elderly patients or those with comorbidities (e.g., CKD, cirrhosis, heart failure).
  • Be mindful of drug interactions: NSAIDs can blunt diuretic effects; certain antibiotics and other drugs can affect proximal tubule secretion of loop diuretics; RAAS inhibitors increase hyperkalemia risk with K+-sparing agents.
  • SGLT2 inhibitors offer renal and cardiac protection beyond glucose lowering, but initial declines in GFR are expected; monitor kidney function and consider patient-specific factors (e.g., CKD stage, concurrent nephrotoxic drugs).
  • In hyponatremia, carefully choose diuretic class; loops may be safer for hyponatremia risk compared with thiazides in certain contexts; vaptans offer targeted ADH antagonism but require liver monitoring in PKD and cirrhosis contexts.

Case Study Answers (Key Points)

  • What led to acute kidney injury (AKI) in the case?
    • Excessive diuresis due to adding HCTZ to chronic loop diuretic therapy in a patient with CKD led to hypovolemia and AKI.
  • What is the reason for weight loss?
    • Rapid diuresis causing volume depletion and loss of body water, especially with the added diuretic load.
  • What precautions could have been taken to avoid hospitalization?
    • Careful titration and monitoring when initiating a thiazide on top of loop therapy; consider inpatient initiation with serial checks (creatinine, electrolytes, weight, BP); review CKD status and avoid aggressive diuresis in the setting of reduced renal function; consider alternative strategies (e.g., lower dose, alternate days dosing, or delaying combination therapy until renal function stabilized).

Quick Reference: Summary by Drug Class (For Exam Preparation)

  • Carbonic anhydrase inhibitors: PCT diuresis; bicarbonate loss; metabolic acidosis; glaucoma and mountain sickness uses; limited diuretic role due to acidosis risk.
  • SGLT2 inhibitors: Glucose and Na+ reabsorption blockers; cardio- and renoprotective effects; CKD benefit; careful with CKD stage; potential AKI signals.
  • Loop diuretics: Most potent diuretics; NKCC2 inhibition; major for edema; strong K+ loss risk; NSAID interactions reduce effect; ototoxicity risk.
  • Thiazides: NCC inhibitors; hyponatremia and hyperglycemia risk; may improve calcium reabsorption; useful for hypertension and idiopathic hypercalciuria; metolazone useful in loop-resistant cases.
  • Potassium-sparing diuretics: MR antagonists and ENaC inhibitors; hyperkalemia risk; gynecomastia risk with spironolactone; useful in resistant hypertension and CKD contexts.
  • Osmotic diuretics: Mannitol; rapidly acting; risk of extracellular volume expansion and hyponatremia; used for intracranial pressure and toxin removal.
  • ADH antagonists (vaptans): Correct hyponatremia in SIADH and HF; monitor for liver toxicity (tolvaptan); IV conivaptan provides V1a and V2 blockade; selectivity matters for safety profile.
  • Urearetics: Aquaretics; potential future use; currently experimental.

Illustrative Connections to Foundational Principles

  • Fluid and electrolyte homeostasis hinge on coordinated transporter activity across nephron segments; blocking specific transporters shifts Na+, water, and electrolyte handling and thereby impacts volume status, BP, and acid-base balance.
  • Hormonal regulation (aldosterone, ADH, PTH) integrates with transporter function to adjust absorption and secretion in the collecting ducts, TAL, and DCT, shaping diuretic responses and potassium balance.
  • Pharmacodynamic synergy (e.g., loop + thiazide) reflects compensation and redundancy in nephron transport; depleting Na+ at multiple sites yields greater diuresis but increases risk for electrolyte disturbances.
  • Pharmacokinetic differences (oral bioavailability, renal vs hepatic clearance) influence drug selection in CKD and liver disease, and explain why some diuretics are favored in certain comorbid conditions.

Notes on LaTeX Formatting in This Document

  • All key transporter motifs and ion transport concepts are represented with LaTeX notation for precision:
    • NKCC2: extNa++extK++2extCl−ext{Na}^+ + ext{K}^+ + 2 ext{Cl}^- cotransport
    • NCC: ext{Na}^+ + ext{Cl}^-
      ightarrow ext{NaCl reabsorption}
    • ENaC and transepithelial potential: 10−50 mV10-50~\text{mV} lumen-negative potential driving Cl− and K+ movements
  • Percentages and proportions from nephron segment reabsorption are given in LaTeX for clarity: 66%66\% Na+ in PCT; 85%85\% NaHCO3; 60%60\% water; glucose and amino acids ~100%.